NCT05816785 is a EARLY_PHASE1 clinical trial of Cetuximab in Head and Neck Cancer, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT05816785?

NCT05816785 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT05816785?

Interventions in NCT05816785: Cetuximab, Imatinib.

What condition does NCT05816785 study?

NCT05816785 studies Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck.

Is NCT05816785 still recruiting?

NCT05816785 is currently active, enrolled. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT05816785

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Active, enrolled EARLY_PHASE1 Last updated 3 September 2025

What this trial tests

EARLY_PHASE1 trial testing Cetuximab in Head and Neck Cancer in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 April 2023

Primary endpoint
30 April 2026

30 April 2026

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	18 April 2023
Primary completion	30 April 2026
Estimated completion	30 April 2026
Sites	1 location across United States

Drugs / interventions tested

Cetuximab (cetuximab) — full drug profile →
Imatinib — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Squamous Cell Carcinoma of Head and Neck — all drugs for Squamous Cell Carcinoma of Head and Neck →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Head and Neck Cancer or Squamous Cell Carcinoma of Head and Neck. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your primary cancer. Participants will undergo a research blood draw and a research biopsy as part of the screening process, and will be in this research study for approximately 13 to 16 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review.
Muehlebach ME, Pradeep S, Chen X, Arnold L, et al · · 2025 · PMID 41439988 · DOI 10.3390/cells14241969

Verify or expand the search:

Other trials of Cetuximab

Trials testing the same drug.

NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT06418724 — Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT07411599 — Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out · Phase 1, PHASE2 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05816785 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05816785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing